Caricamento azienda
Just reported
From Halozyme Therapeutics's results release of 5 novembre 2026; its quarterly report has since been filed.
Actual
493M USD
+39% y/y
+2,5% q/q
Guided
—
No guide given
Actual
2,01 USD
+41% y/y
+5,8% q/q
Guided
—
No guide given
EPS, adjusted: 2,39 USD
The themes Halozyme Therapeutics is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.47,6B USDA+
EXELExelixis, Inc.16,8B USDA+
JAZZJazz Pharmaceuticals plc15,5B USDA
TECHBIO-Techne Corp11,4B USDA+
TGTXTG Therapeutics, Inc.9,7B USDA+Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 ott 2026CBGraded C, now B
MCKMckesson Corporation4 nov 2026BAGraded B, now A
CVSCVS Health Corp4 nov 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 ott 2026CAGraded C, now ACostruito dai documenti depositati da Halozyme Therapeutics, Inc. presso la Securities and Exchange Commission (SEC), l’autorità di vigilanza statunitense. Le cifre sono quelle dichiarate, con lo storico per azione ricalcolato sulla base azionaria di oggi. Questo descrive un’azienda: non è consulenza finanziaria né una raccomandazione di acquisto o vendita.
Previsione dell’azienda: ricavi di da 1,9B USD a 1,9B USD per Esercizio 2026 — in crescita del 35,5% sull'anno precedente
Actual
295M USD
+35% y/y
+2,5% q/q
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Grade A+
La fascia sotto il prezzo mostra il voto in ogni data, calcolato solo sui documenti già pubblici in quel momento.
Mostra 2 trimestri su 41 dello storico dei voti di Halozyme Therapeutics, Inc.. Gli altri 39 risalgono fino a novembre 2016.
